

**From:** Liverpool-ECMC  
**Sent:** 06 December 2019 17:10  
**To:** Liverpool-ECMC  
**Subject:** Liverpool ECMC Newsletter December 2019 - Solids

**Follow Up Flag:** Follow up  
**Flag Status:** Completed

## LIVERPOOL ECMC NEWSLETTER DECEMBER 2019



### UK-EDI LAUNCH

A new CR-UK funded programme, the UK Early Detection Initiative for Pancreatic Cancer (UK-EDI), was launched in Liverpool on the 20th November, the eve of World Pancreatic Cancer Day.

The programme aims to investigate the link between the development of new onset diabetes in patients diagnosed with pancreatic cancer in order to develop a test to detect pancreatic cancer earlier.

The programme is led by Professor Eithne Costello from the University of Liverpool and is looking to recruit 2500 participants aged 50 or over who have recently developed new onset diabetes. UK-EDI is supported by the Liverpool ECMC.

For further information on the programme please contact the study team at [ukedi@liv.ac.uk](mailto:ukedi@liv.ac.uk).

# PSGBI ANNUAL MEETING



The Pancreatic Society of Great Britain and Ireland (PSGBI) chose to hold its annual meeting in Liverpool on the 21st and 22nd of November, coinciding with World Pancreas Day and the University lit up the engineering building in purple to mark the occasion.



Leading pancreatologists from across Europe gathered for the meeting, which was held in the Metropolitan Cathedral and featured presentations from ECMC researchers from Liverpool and elsewhere, including the President of the Society, Prof. Bill Greenhalf, who is also the scientific lead for our ECMC.

## LIVERPOOL ECMC EARLY PHASE TRIALS CLINIC IS OPEN



The ECMC Early Phase Trials Clinic is open. This weekly clinic runs every Monday afternoon at the Clatterbridge Cancer Centre.

Patients who are potentially eligible and interested in participating in phase I and non-randomised phase II clinical trials can be referred to this clinic via the following email address: [ccf-tr.ecmcreferrals@nhs.net](mailto:ccf-tr.ecmcreferrals@nhs.net).



## NEW EARLY PHASE TRIAL OPEN - CT7001\_001

The **CT7001\_001** trial is now open for recruitment. This is a phase I/II study of CT7001 in combination with fulvestrant in patients with advanced hormone receptor positive breast cancer. CT7001 inhibits the CDK7 enzyme.

In Part A participants will be enrolled in a dose escalation phase of two dose level cohorts of CT7001.

### KEY INCLUSION CRITERIA

- Histologically confirmed diagnosis of carcinoma of the breast with evidence of metastatic or locally advanced disease, not amenable to resection or radiation therapy with curative intent.
- Documentation of estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive tumour based on most recent tumour biopsy.
- Documentation of HER2 negativity based on most recent tumour biopsy.
- ECOG performance status 0-1.

Patients can be referred via [ccf-tr.ecmcreferrals@nhs.net](mailto:ccf-tr.ecmcreferrals@nhs.net).

## OPEN TRIALS

Please contact **Jennie Derham** for potential referral to these trials.

- Telephone: 0151 556 5443
- Mobile: 07554 416 293
- E-mail: [ccf-tr.ecmcreferrals@nhs.net](mailto:ccf-tr.ecmcreferrals@nhs.net)



## ADVANCED SOLID TUMOURS

- **ACIT-1** – A Phase I clinical study to determine the optimal dose for the safe immune restoration and immune response of allogeneic cell immunotherapy (ACIT-1) in adult cancer patients – *All advanced solid tumours*.
- **BEIGENE BGB-290-106** – A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib following Single Oral Dose Administration in Patients with Advanced and/or Metastatic Solid Tumors - *Advanced / metastatic solid tumours*.
- **REPLIMUNE RP1** – An Open-Label, Multicenter, Phase 2 Study of RPI in Combination with Nivolumab in Patients with Microsatellite Instability High or Mismatch Repair Deficient Tumors – *Melanoma, Non-Melanoma Skin Cancer, Urothelial Bladder Carcinoma*.
- **REPLIMUNE RP2** – An Open-Label, Multicenter, Phase 1 Study of RP2 as a Single Agent and in Combination with PD1 Blockade in Patients *with Solid Tumors*

## BREAST

- **CT7001 001** – A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies– *Advanced breast cancer*.
- **GO40987** – A Phase I, Multicenter, Open-Label Preoperative, Short-Term Window Study of GDC-9545 in Postmenopausal Women with *Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer*
- **plasmaMATCH** – A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy

for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening – *Advanced breast cancer*.

## HEAD & NECK

- **Cambridge Brain Mets Trial 1** – A proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy – *Brain metastases from lung or breast primary*.
- **NICO** – Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in oral cavity cancer – *squamous cell carcinoma of the oral cavity*.

## HPB / UPPER GI

- **OUTREACH** – A First-in-Human, multi-centre, open-label, Phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer (OUTREACH) – Advanced liver cancer.
- **POLARIS** - Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma - *Hepatocellular Carcinoma*

## MELANOMA

- **CirculAting Tumour DNA gUided therapy Switch (CAcTUS)** – A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumour DNA in guiding a switch between targeted therapy and immune therapy in patients with *advanced cutaneous melanoma*.

## NON-CTIMPS

- **HYST** – Hypersensitivity Study: A Mechanistic Investigation into Drug and Chemical Induced Hypersensitivity Reactions
- **PRIMM** – Predicting Response to Immunotherapy for Melanoma with gut Microbiome and metabolomics (the PRIMM study)
- **PROACT** – Patient Reported Opinions About Clinical Tolerability
- **SMP-2** – The Cancer Research UK Stratified Medicine Programme: Pilot Study

[Find out more...](#)

## EVENTS & JOB OPPORTUNITIES

### EVENTS

- [ECMC Junior Investigator Network Group: Training the Next Generation \(FEBRUARY 2020\)](#)
- <https://www.ecmcnetwork.org.uk/events>

## CONTACT US

If you require any information which isn't on the newsletter please contact the Liverpool ECMC Team via [e-mail](#).

*Copyright © 2019 Liverpool ECMC, All rights reserved.*

Our mailing address is:

[livecmc@liv.ac.uk](mailto:livecmc@liv.ac.uk)